HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Vaziri, N. D. Search for Related Content PubMed PubMed Citation Articles by Vaziri, N. D.

INVITED REVIEW

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

Division of Nephrology and Hypertension, University of California, Irvine, California

Chronic renal failure (CRF) results in profound lipid disorders, which stem largely from dysregulation of high-density lipoprotein (HDL) and triglyceride-rich lipoprotein metabolism. Specifically, maturation of HDL is impaired and its composition is altered in CRF. In addition, clearance of triglyceride-rich lipoproteins and their atherogenic remnants is impaired, their composition is altered, and their plasma concentrations are elevated in CRF. Impaired maturation of HDL in CRF is primarily due to downregulation of lecithin-cholesterol acyltransferase (LCAT) and, to a lesser extent, increased plasma cholesteryl ester transfer protein (CETP). Triglyceride enrichment of HDL in CRF is primarily due to hepatic lipase deficiency and elevated CETP activity. The CRF-induced hypertriglyceridemia, abnormal composition, and impaired clearance of triglyceride-rich lipoproteins and their remnants are primarily due to downregulation of lipoprotein lipase, hepatic lipase, and the very-low-density lipoprotein receptor, as well as, upregulation of hepatic acyl-CoA cholesterol acyltransferase (ACAT). In addition, impaired HDL metabolism contributes to the disturbances of triglyceride-rich lipoprotein metabolism. These abnormalities are compounded by downregulation of apolipoproteins apoA-I, apoA-II, and apoC-II in CRF. Together, these abnormalities may contribute to the risk of arteriosclerotic cardiovascular disease and may adversely affect progression of renal disease and energy metabolism in CRF.

chronic kidney disease; lipid disorders; cardiovascular disease; high-density lipoprotein metabolism; cholesterol metabolism; triglyceride

This article has been cited by other articles:

				H. Kastarinen, S. Horkko, H. Kauma, A. Karjalainen, M. J. Savolainen, and Y. A. Kesaniemi Low-density lipoprotein clearance in patients with chronic renal failure Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2131 - 2135. [Abstract] [Full Text] [PDF]

				P. Meier, D. Golshayan, E. Blanc, M. Pascual, and M. Burnier Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1368 - 1384. [Abstract] [Full Text] [PDF]

				B. C. Fellstrom, A. G. Jardine, R. E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D.-W. Chae, A. Chevaile, S. M. Cobbe, C. Gronhagen-Riska, et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis N. Engl. J. Med., April 2, 2009; 360(14): 1395 - 1407. [Abstract] [Full Text] [PDF]

				G Ferns, V Keti, and B Griffin Investigation and management of hypertriglyceridaemia J. Clin. Pathol., November 1, 2008; 61(11): 1174 - 1183. [Abstract] [Full Text] [PDF]

				H.-Y. Yu, J.-Y. Li, S. Sun, K.-Y. Hung, J.-L. Wang, Y.-S. Chen, S.-S. Wang, and F.-Y. Lin Late dialysis rate for coronary artery bypass grafting patients with moderate-to-severe renal impairment: comparison between off-pump and conventional method Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 364 - 369. [Abstract] [Full Text] [PDF]

				Y. Quiroz, A. Ferrebuz, F. Romero, N. D. Vaziri, and B. Rodriguez-Iturbe Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction Am J Physiol Renal Physiol, February 1, 2008; 294(2): F336 - F344. [Abstract] [Full Text] [PDF]

				I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 125 - 132. [Abstract] [Full Text] [PDF]

				C. A. Bang, S. Bro, E. D. Bartels, T. X. Pedersen, and L. B. Nielsen Effect of uremia on HDL composition, vascular inflammation, and atherosclerosis in wild-type mice Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1325 - F1331. [Abstract] [Full Text] [PDF]

				C. L. Weber, J. Frohlich, J. Wang, R. A. Hegele, and C. Chan-Yan Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2084 - 2088. [Full Text] [PDF]

				R. C. Ozsoy, W. A. van der Steeg, J. J. P. Kastelein, L. Arisz, and M. G. Koopman Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1578 - 1586. [Abstract] [Full Text] [PDF]